• What is the risk of rhabdomyolysis in patients taking both SGLT2 inhibitors and statins?

  • Nov 19 2024
  • Length: 5 mins
  • Podcast

What is the risk of rhabdomyolysis in patients taking both SGLT2 inhibitors and statins?

Listen for free

View show details

  • Summary

  • In this podcast, a study from Ontario revealed that SGLT2 inhibitors, when combined with statins, were associated with a 25% lower risk of rhabdomyolysis compared to DPP4 inhibitors. A phase I trial at Washington University demonstrated promising outcomes for a neoantigen DNA vaccine aimed at preventing recurrence in triple-negative breast cancer (TNBC). Finally, intensive systolic blood pressure control in Chinese patients with type 2 diabetes and elevated cardiovascular risk significantly reduced major cardiovascular events compared to standard care.
    Show more Show less
Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about What is the risk of rhabdomyolysis in patients taking both SGLT2 inhibitors and statins?

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available